Epacadostat, Idarubicin and Cytarabine (EIC) in AML
Status:
Withdrawn
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting
toxicities (DLTs) of epacadostat when added to the anthracycline/cytarabine combination as
first-line induction treatment in AML patients fit for intensive treatment